Drug intelligence / Profile preview

Esano ACA

Development stage: Unknown
Lead developer: Alerce Biologix
Administration: Topical

Overview

Esano ACA is a placenta-derived tissue biologic developed by Alerce Biologix for advanced wound care applications. As an amniotic-chorionic membrane allograft (ACA), it is processed using proprietary tissue technology to preserve the natural structural and biochemical properties of the placental tissue, including a complex extracellular matrix and a variety of endogenous growth factors and cytokines. The product acts as a biological scaffold that supports cellular attachment, migration, and proliferation, while also providing a protective barrier for the wound bed. It is primarily indicated for the treatment of chronic and acute wounds, such as diabetic foot ulcers and venous leg ulcers, where it helps to accelerate the regenerative process and improve patient outcomes.

Brand names: Esano ACA
Other names: Amniotic Chorionic Allograft

Beyond the preview

Go deeper on Esano ACA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Esano ACA.

Explore the full profile